Baron Andreas, Bilzer Manfred, Gerbes Alexander L
Department of Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377 Munich, Germany.
Transpl Int. 2002 Jun;15(6):265-71. doi: 10.1007/s00147-002-0379-z. Epub 2002 Apr 16.
Mycophenolate mofetil (MMF) is a new immunosuppressive agent which has been used successfully after kidney and heart transplantation. Experience with MMF after liver transplantation is still limited. In particular, there is no information about influence on ischemia-reperfusion injury (IRI). Therefore, the aim of this investigation was to assess the effects of mycophenolic acid (MPA), the pharmacologically active metabolite of MMF, in the cold-preserved or normal rat liver. Livers of male Sprague-Dawley rats were subjected to cold ischemia in University of Wisconsin (UW) solution (24 h, 4 degrees C) and reperfused for 2 h in the absence or presence of MPA (100 microg/ml, n=5-6 each). Another group received MPA pretreatment for 20 min prior to ischemia ( n=7). In further experiments, livers were perfused with a bile salt-free Krebs-Henseleit buffer in a continuous fashion (controls, n=5). MPA was infused from 20-40 min after starting perfusion in therapeutic concentrations (5 microg/ml, 10 microg/ml, 40 microg/ml, and 100 microg/ml; n=3-6 each). There was no significant influence of MPA on portal pressure nor on postischemic efflux rates of LDH. MPA pretreatment resulted in a significant improvement of bile flow during reperfusion (0.32+/-0.05 microl/min x g liver) compared with controls (0.17+/-0.04 microl/min x g liver, mean+/-SEM). In contrast, postischemic bile flow was not influenced by continuous administration of MPA during the reperfusion period only (0.18+/-0.07 microl/min x g liver). In continuously perfused livers, MPA increased bile salt-independent bile flow (1.00+/-0.06 microl/min x g liver) in a dose-dependent manner, reaching half-maximal effects around 5 microg/ml (1.66+/-0.15 microl/min x g liver) and maximal effects at 40 microg/ml (2.61+/-0.28 microl/min x g liver). In conclusion, neither preischemic nor postischemic administration of MPA influences IRI to hepatocytes significantly after hypothermic liver preservation in UW solution. In contrast to other immunosuppressive agents, MPA exhibits strong choleretic effects, which are related to a stimulation of bile salt-independent bile formation.
霉酚酸酯(MMF)是一种新型免疫抑制剂,已成功应用于肾移植和心脏移植术后。肝移植后使用MMF的经验仍然有限。特别是,关于其对缺血再灌注损伤(IRI)的影响尚无相关信息。因此,本研究的目的是评估MMF的药理活性代谢产物霉酚酸(MPA)对冷保存或正常大鼠肝脏的影响。雄性Sprague-Dawley大鼠的肝脏在威斯康星大学(UW)溶液中进行冷缺血(24小时,4℃),然后在不存在或存在MPA(100μg/ml,每组n = 5 - 6)的情况下再灌注2小时。另一组在缺血前接受MPA预处理20分钟(n = 7)。在进一步的实验中,肝脏以连续方式用无胆盐的Krebs-Henseleit缓冲液灌注(对照组,n = 5)。在开始灌注后20 - 40分钟以治疗浓度(5μg/ml、10μg/ml、40μg/ml和100μg/ml;每组n = 3 - 6)输注MPA。MPA对门静脉压力和缺血后LDH流出率均无显著影响。与对照组(0.17±0.04μl/min×g肝脏,平均值±标准误)相比,MPA预处理导致再灌注期间胆汁流量显著改善(0.32±0.05μl/min×g肝脏)。相比之下,仅在再灌注期间连续给予MPA对缺血后胆汁流量无影响(0.18±0.07μl/min×g肝脏)。在连续灌注的肝脏中,MPA以剂量依赖性方式增加不依赖胆盐的胆汁流量(1.00±0.06μl/min×g肝脏),在约5μg/ml时达到最大效应的一半(1.66±0.15μl/min×g肝脏),在40μg/ml时达到最大效应(2.61±0.28μl/min×g肝脏)。总之,在UW溶液中低温保存肝脏后,缺血前或缺血后给予MPA均未显著影响肝细胞的IRI。与其他免疫抑制剂不同,MPA具有强大的利胆作用,这与刺激不依赖胆盐的胆汁形成有关。